X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2231) 2231
humans (2185) 2185
bortezomib (1401) 1401
male (1312) 1312
female (1156) 1156
pyrazines - therapeutic use (1109) 1109
middle aged (1068) 1068
pyrazines - adverse effects (1059) 1059
pyrazines - administration & dosage (918) 918
aged (904) 904
multiple myeloma - drug therapy (770) 770
adult (735) 735
oncology (706) 706
boronic acids - adverse effects (673) 673
boronic acids - administration & dosage (662) 662
boronic acids - therapeutic use (619) 619
treatment outcome (591) 591
hematology (524) 524
multiple myeloma (511) 511
pyrazines - pharmacology (478) 478
antineoplastic combined chemotherapy protocols - therapeutic use (470) 470
animals (451) 451
antineoplastic agents - therapeutic use (432) 432
sitagliptin phosphate (401) 401
antineoplastic agents - adverse effects (399) 399
diabetes mellitus, type 2 - drug therapy (339) 339
antineoplastic combined chemotherapy protocols - adverse effects (293) 293
therapy (292) 292
aged, 80 and over (290) 290
pharmacology & pharmacy (289) 289
care and treatment (286) 286
triazoles - therapeutic use (265) 265
cancer (251) 251
dexamethasone - administration & dosage (238) 238
dexamethasone (230) 230
drug therapy, combination (229) 229
hypoglycemic agents - therapeutic use (228) 228
dose-response relationship, drug (226) 226
thalidomide (214) 214
research (211) 211
thalidomide - analogs & derivatives (210) 210
chemotherapy (209) 209
drug therapy (209) 209
abridged index medicus (201) 201
boronic acids - pharmacology (201) 201
antineoplastic agents - administration & dosage (199) 199
triazoles - adverse effects (197) 197
mice (196) 196
stem-cell transplantation (195) 195
thalidomide - administration & dosage (189) 189
medicine & public health (186) 186
multiple-myeloma (184) 184
drug administration schedule (179) 179
endocrinology & metabolism (179) 179
recurrence (176) 176
sitagliptin (175) 175
type 2 diabetes (175) 175
clinical trials as topic (174) 174
protease inhibitors - therapeutic use (171) 171
apoptosis (169) 169
trial (168) 168
proteasome inhibitors (165) 165
hypoglycemic agents - adverse effects (161) 161
hematology, oncology and palliative medicine (154) 154
analysis (153) 153
multiple myeloma - pathology (153) 153
thalidomide - therapeutic use (151) 151
dosage and administration (147) 147
transplantation (146) 146
diabetes (145) 145
rats (142) 142
retrospective studies (140) 140
proteasome inhibitor bortezomib (138) 138
disease-free survival (137) 137
pyrazines - pharmacokinetics (136) 136
clinical trials (135) 135
dipeptidyl-peptidase iv inhibitors - therapeutic use (134) 134
antineoplastic agents - pharmacology (132) 132
article (131) 131
multiple myeloma - mortality (129) 129
multiple myeloma - therapy (127) 127
time factors (127) 127
medicine, general & internal (126) 126
triazoles - administration & dosage (126) 126
double-blind method (125) 125
lenalidomide (125) 125
survival (125) 125
combination (124) 124
efficacy (123) 123
risk factors (123) 123
double-blind (120) 120
follow-up studies (120) 120
prognosis (119) 119
peripheral neuropathy (118) 118
multiple myeloma - complications (117) 117
hypoglycemic agents - administration & dosage (116) 116
protease inhibitors - adverse effects (116) 116
thalidomide - adverse effects (116) 116
peripheral nervous system diseases - chemically induced (115) 115
antineoplastic combined chemotherapy protocols - administration & dosage (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2276) 2276
Japanese (41) 41
Chinese (32) 32
German (26) 26
French (20) 20
Italian (11) 11
Spanish (11) 11
Swedish (6) 6
Russian (5) 5
Polish (4) 4
Czech (3) 3
Danish (3) 3
Hebrew (2) 2
Norwegian (2) 2
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2778 - 2788
AimsBased on in vitro data, there is evidence to suggest that cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite,... 
pharmacokinetics | rifampicin | selexipag | CYP2C8 | drug interactions | gemfibrozil | PULMONARY ARTERIAL-HYPERTENSION | TREPROSTINIL | REPAGLINIDE | CLOPIDOGREL | CONCISE GUIDE | PHARMACOLOGY | TOLERABILITY | PROSTACYCLIN RECEPTOR AGONIST | PHARMACOLOGY & PHARMACY | INHIBITOR | Prodrugs - administration & dosage | Activation, Metabolic | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Acetates - adverse effects | Acetates - blood | Area Under Curve | Humans | Middle Aged | Pyrazines - administration & dosage | Antihypertensive Agents - administration & dosage | Half-Life | Male | Metabolic Clearance Rate | Gemfibrozil - adverse effects | Healthy Volunteers | Acetamides - blood | Young Adult | Rifampin - adverse effects | Drug Interactions | Acetamides - adverse effects | Cytochrome P-450 CYP2C8 Inducers - adverse effects | Adult | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Cytochrome P-450 CYP2C8 Inducers - administration & dosage | Acetamides - pharmacokinetics | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Prodrugs - adverse effects | Acetates - administration & dosage | Prodrugs - pharmacokinetics | Pyrazines - pharmacokinetics | Adolescent | Pyrazines - adverse effects | Pyrazines - blood | Germany | Acetamides - administration & dosage | Acetates - pharmacokinetics | Metabolites | Gemfibrozil | Cytochrome P-450 | Nausea | Drug therapy, Combination | Rifampin | Fibric acids | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2007, Volume 9, Issue 2, pp. 194 - 205
Journal Article
Transplantation, ISSN 0041-1337, 12/2008, Volume 86, Issue 12, pp. 1754 - 1761
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3830 - 3835
Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | MANTLE-CELL LYMPHOMA | IN-VITRO | ONCOLOGY | PROTEASOME INHIBITOR BORTEZOMIB | NON-HODGKINS-LYMPHOMA | PHASE-II | RELAPSED MULTIPLE-MYELOMA | CHOP-R | COOPERATIVE-ONCOLOGY-GROUP | Herpes Zoster - prevention & control | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal - adverse effects | Hematocrit | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Waldenstrom Macroglobulinemia - pathology | Waldenstrom Macroglobulinemia - drug therapy | Aged, 80 and over | Female | Boronic Acids - administration & dosage | Waldenstrom Macroglobulinemia - blood | Antibodies, Monoclonal, Murine-Derived | Bortezomib | Dexamethasone - administration & dosage | Drug Administration Schedule | Blood Viscosity - drug effects | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Bone Marrow Neoplasms - secondary | Herpes Zoster - chemically induced | Disease-Free Survival | Immunoglobulin M - blood | Platelet Count | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Aged | Bone Marrow Neoplasms - drug therapy | Index Medicus | Original Reports | Hema15 | Bios3 | Hema23
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 426 - 435
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 11, pp. 1968 - 1975
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2009, Volume 15, Issue 16, pp. 5250 - 5257
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 659 - 667
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 10/2008, Volume 24, Issue 10, pp. 2943 - 2952
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 04/2011, Volume 65, Issue 4, pp. 397 - 407
Journal Article
Journal Article